CRSP
EquityCRISPR Therapeutics AG
Health Care · Biotechnology
$59.17
+59.17 (+0.00%)
Open
N/A
Day Range
$57.75 - $60.46
52W Range
$30.04 - $78.48
Volume
387K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Assessing CRISPR Therapeutics (CRSP) Valuation After FDA Draft Guidance And Recent Weak Earnings
FDA Draft Guidance Puts CRISPR Therapeutics Rare Disease Outlook In Focus
CRISPR Therapeutics Stock Sees RS Rating Rise To 73
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | $233.86 | N/A | 2.84% | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.27 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $22.50 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.66 | N/A | - | +0.00% |
| A | Agilent Technologies, Inc. | $120.25 | N/A | 0.83% | +0.00% |
| ABT | Abbott Laboratories | $113.84 | N/A | 2.11% | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.68 | N/A | - | +0.00% |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
www.crisprtx.com →🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for CRSP
🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for CRSP.